WO1997001344A3 - Procede de ralentissement dynamique de la cinetique du cycle cellulaire, destine a potentialiser les lesions cellulaires - Google Patents

Procede de ralentissement dynamique de la cinetique du cycle cellulaire, destine a potentialiser les lesions cellulaires Download PDF

Info

Publication number
WO1997001344A3
WO1997001344A3 PCT/US1996/010921 US9610921W WO9701344A3 WO 1997001344 A3 WO1997001344 A3 WO 1997001344A3 US 9610921 W US9610921 W US 9610921W WO 9701344 A3 WO9701344 A3 WO 9701344A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitor
tci
agents
staurosporine
administering
Prior art date
Application number
PCT/US1996/010921
Other languages
English (en)
Other versions
WO1997001344A2 (fr
Inventor
Philip M Grimley
Sunil Mehta
Original Assignee
Jackson H M Found Military Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jackson H M Found Military Med filed Critical Jackson H M Found Military Med
Priority to EP96923453A priority Critical patent/EP0835111A2/fr
Priority to JP9504545A priority patent/JPH11509193A/ja
Priority to AU63960/96A priority patent/AU715527B2/en
Priority to CA002225682A priority patent/CA2225682A1/fr
Publication of WO1997001344A2 publication Critical patent/WO1997001344A2/fr
Publication of WO1997001344A3 publication Critical patent/WO1997001344A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention se rapporte à un procédé amélioré destiné à induire des lésions cellulaires, par l'administration d'un agent de ralentissement (RA) à une population cellulaire cible en une concentration suffisante et dans des conditions appropriées pour retarder, mais non interrompre la progression des cellules cibles dans le cycle cellulaire, et l'administration simultanée ou ultérieure à celle de l'agent de ralentissement, d'un agent d'agression cytotoxique ciblé (TCI). L'invention se rapporte également à un système indicateur en microculture et à des procédures d'analyse de données auxiliaires visant à identifier, concevoir et utiliser de nouveaux agents comme agents de ralentissement ou agents d'agression cytotoxiques ciblés, ainsi qu'à améliorer les associations synergiques des agents existants. Dans des modes de réalisation de l'invention, l'agent de ralentissement peut être un inhibiteur de ribonucléotide réductase, de dihydrofolate réductase, de thymidylate synthase, d'ADN polymérase, de protéine kinase ou de topoisomérase. En outre, selon des variantes de l'invention on utilise, comme agent TCI, les indole carbazoles tels que la staurosporine, K252a, KT5926, et KT5720. Dans une variante spécifique, l'agent de ralentissement est la thymidine et l'agent TCI est la staurosporine.
PCT/US1996/010921 1995-06-27 1996-06-26 Procede de ralentissement dynamique de la cinetique du cycle cellulaire, destine a potentialiser les lesions cellulaires WO1997001344A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP96923453A EP0835111A2 (fr) 1995-06-27 1996-06-26 Procede de ralentissement dynamique de la cinetique du cycle cellulaire, destine a potentialiser les lesions cellulaires
JP9504545A JPH11509193A (ja) 1995-06-27 1996-06-26 細胞傷害を増強するための細胞周期動力学の動的遅延方法
AU63960/96A AU715527B2 (en) 1995-06-27 1996-06-26 Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
CA002225682A CA2225682A1 (fr) 1995-06-27 1996-06-26 Procede de ralentissement dynamique de la cinetique du cycle cellulaire, destine a potentialiser les lesions cellulaires

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54695P 1995-06-27 1995-06-27
US66893296A 1996-06-24 1996-06-24
US08/668,932 1996-06-24
US60/000,546 1996-06-24

Publications (2)

Publication Number Publication Date
WO1997001344A2 WO1997001344A2 (fr) 1997-01-16
WO1997001344A3 true WO1997001344A3 (fr) 1997-03-27

Family

ID=26667798

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/010921 WO1997001344A2 (fr) 1995-06-27 1996-06-26 Procede de ralentissement dynamique de la cinetique du cycle cellulaire, destine a potentialiser les lesions cellulaires

Country Status (5)

Country Link
EP (1) EP0835111A2 (fr)
JP (1) JPH11509193A (fr)
AU (1) AU715527B2 (fr)
CA (1) CA2225682A1 (fr)
WO (1) WO1997001344A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010510222A (ja) * 2006-11-17 2010-04-02 シェーリング コーポレイション 増殖性障害に対する併用療法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4448534A (en) * 1978-03-30 1984-05-15 American Hospital Corporation Antibiotic susceptibility testing
EP0359981A1 (fr) * 1988-08-18 1990-03-28 Roche Diagnostics GmbH Compositions pharmaceutiques et leur utilisation comme médicament antinéoplaste
WO1991007180A1 (fr) * 1989-10-13 1991-05-30 City Of Hope Amelioration de la resistance humaine aux medicaments antitumoraux
WO1992019765A1 (fr) * 1991-05-08 1992-11-12 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Procede de conception de traitements du cancer, procedes et compositions pharmaceutiques de traitements du cancer
WO1993000909A1 (fr) * 1991-07-03 1993-01-21 Regeneron Pharmaceuticals, Inc. Procede et systeme de determination de l'activite de la neurotrophine
WO1993009782A1 (fr) * 1991-11-15 1993-05-27 Smithkline Beecham Corporation Chimiotherapie combinee
WO1994004541A2 (fr) * 1992-08-12 1994-03-03 The Upjohn Company Inhibiteurs de proteine kinase et composes apparentes combines avec du taxol
WO1994018990A1 (fr) * 1993-02-26 1994-09-01 Research Development Foundation Combinaison de cisplatine/tamoxifen pour le traitement therapeutique des cancers chez l'homme
WO1995000520A1 (fr) * 1993-06-17 1995-01-05 Ciba-Geigy Ag Compose d'indolocarbazole utilise comme inhibiteur de proteine-kinase c

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4448534A (en) * 1978-03-30 1984-05-15 American Hospital Corporation Antibiotic susceptibility testing
EP0359981A1 (fr) * 1988-08-18 1990-03-28 Roche Diagnostics GmbH Compositions pharmaceutiques et leur utilisation comme médicament antinéoplaste
WO1991007180A1 (fr) * 1989-10-13 1991-05-30 City Of Hope Amelioration de la resistance humaine aux medicaments antitumoraux
WO1992019765A1 (fr) * 1991-05-08 1992-11-12 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Procede de conception de traitements du cancer, procedes et compositions pharmaceutiques de traitements du cancer
WO1993000909A1 (fr) * 1991-07-03 1993-01-21 Regeneron Pharmaceuticals, Inc. Procede et systeme de determination de l'activite de la neurotrophine
WO1993009782A1 (fr) * 1991-11-15 1993-05-27 Smithkline Beecham Corporation Chimiotherapie combinee
WO1994004541A2 (fr) * 1992-08-12 1994-03-03 The Upjohn Company Inhibiteurs de proteine kinase et composes apparentes combines avec du taxol
WO1994018990A1 (fr) * 1993-02-26 1994-09-01 Research Development Foundation Combinaison de cisplatine/tamoxifen pour le traitement therapeutique des cancers chez l'homme
WO1995000520A1 (fr) * 1993-06-17 1995-01-05 Ciba-Geigy Ag Compose d'indolocarbazole utilise comme inhibiteur de proteine-kinase c

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BENZ, C. ET AL: "Tamoxifen and 5-Fluorouracil in Breast Cancer: Cytotoxic Synergism", CANCER RESEARCH, vol. 43, 1983, pages 5298 - 5303, XP002017534 *
CAPIZZI, R.L. ET AL: "Combination Chemotherapy - Theory and Practice", SEMINARS IN ONCOLOGY, vol. 4, no. 2, 1977, pages 227 - 253, XP002017535 *
CHANG T.T. ET AL: "Synergistic effect of 4-hydroperoxycyclophosphamide and etopside on a human promyelocytic leukemia cell line (HL-60) demonstrated by computer analysis", CANCER RES. (UNITED STATES), vol. 45, no. 6, 1985, pages 2434 - 2439, XP002024374 *
CHOU T.-C. ET AL: "Quantitation of the synergistic interaction of edatrexate and cisplatin in vitro", CANCER CHEMOTHER. PHARMACOL. (GERMANY), vol. 31, no. 4, 1993, XP002024380 *
FRANKFURT,O.S.: "Combination Chemotherapy and DNA Repair Inhibition", ANTICANCER RESEARCH, vol. 12, no. 6A, 1992, pages 1795 - 1796, XP002018044 *
FROST P. ET AL: "Synergistic cytotoxicity using 2'-deoxy-5-azacytidine and cisplatin or 4-hydroperoxycyclophosphamide with human tumor cells", CANCER RES. (UNITED STATES), vol. 50, no. 15, 1990, pages 4572 - 4577, XP002024373 *
GRANT, S. ET AL: "Modulation of 1-[beta-D-Arabinofuranosyl]Cytosine-Induced Apoptosis in Human Myeloid Leukemia Cells by Staurosporine and Other Pharmacological Inhibitors of Protein Kinase C", ONCOLOGY RESEARCH, vol. 6, no. 2, 1994, pages 87 - 99, XP002017533 *
HOFMANN, J. ET AL: "Enhancement of the Antiproliferative Effect of cis-Diamminechloroplatinum (II) and Nitrogen Mustard by Inhibitors of Proteine Kinase C", INT. J. CANCER, vol. 42, 1988, pages 382 - 388, XP002017532 *

Also Published As

Publication number Publication date
WO1997001344A2 (fr) 1997-01-16
EP0835111A2 (fr) 1998-04-15
CA2225682A1 (fr) 1997-01-16
AU715527B2 (en) 2000-02-03
AU6396096A (en) 1997-01-30
JPH11509193A (ja) 1999-08-17

Similar Documents

Publication Publication Date Title
Allaudeen et al. On the mechanism of selective inhibition of herpesvirus replication by (E)-5-(2-bromovinyl)-2'-deoxyuridine.
Rundles et al. Effects of a xanthine oxidase inhibitor on thiopurine metabolism, hyperuricemia and gout
Kinahan et al. Biochemical and antitumor effects of the combination of thymidine and 1-β-D-arabinofuranosylcytosine against leukemia L1210
Boothman et al. Down-regulation of topoisomerase I in mammalian cells following ionizing radiation
Verhoef et al. Identification of the mechanism of activation of 9-β-D-arabinofuranosyladenine in human lymphoid cells using mutants deficient in nucleoside kinases
Kalejta et al. The dual effect of mimosine on DNA replication
Milstien et al. Studies on the phenylalanine hydroxylase system in liver slices.
Parkinson et al. Inhibitory effects of propentofylline on [3H] adenosine influx: a study of three nucleoside transport systems
Elford et al. Effect of methotrexate and 5-fluorodeoxyuridine on ribonucleotide reductase activity in mammalian cells
Smith et al. Metabolic effects and kill of human T-cell leukemia by 5-deazaacyclotetrahydrofolate, a specific inhibitor of glycineamide ribonucleotide transformylase
WO1997001344A3 (fr) Procede de ralentissement dynamique de la cinetique du cycle cellulaire, destine a potentialiser les lesions cellulaires
Momparler Biochemical pharmacology of cytosine arabinoside
Worku et al. Identification of histidyl and cysteinyl residues essential for catalysis by 5′‐nucleotidase
Johnson et al. 2′, 3′-Dideoxynucleoside phosphorylation by deoxycytidine kinase from normal human thymus extracts: activation of potential drugs for AIDS therapy
Bhat et al. Role of poly (ADP–ribose) polymerase (PARP) in DNA repair in sulfur mustard‐exposed normal human epidermal keratinocytes (NHEK)
Kloor et al. Effects of ions on adenosine binding and enzyme activity of purified S-adenosylhomocysteine hydrolase from bovine kidney
Tanaka et al. Altered Sensitivity to 1-β-d-Arabinofuranosylcytosine 5′-Triphosphate of DNA Polymerase α from Leukemic Blasts of Acute Lymphoblastic Leukemia
Yamaguchi et al. Chiral discrimination of enantiomeric 2′-deoxythymidine 5′-triphosphate by HIV-1 reverse transcriptase and eukaryotic DNA polymerases
Pizzorno et al. (6R)-5, 10-Dideaza-5, 6, 7, 8-tetrahydrofolic acid effects on nucleotide metabolism in CCRF-CEM human T-lymphoblast leukemia cells
Watanabe et al. Demonstration of enzymatic activity converting azathioprine to 6-mercaptopurine
Malinoski et al. Inhibition of Sindbis virus replication by ribavirin: Influence of cultural conditions and of the host cell phenotype
Kelly et al. Insulin stimulation of phospholipid methylation in isolated rat adipocyte plasma membranes.
Stellwagen The effects of theophylline and certain other purine derivatives on tyrosine aminotransferase activity in hepatoma cells in culture
Caras et al. Direct photoaffinity labeling of an allosteric site of subunit protein M1 of mouse ribonucleotide reductase by dATP. Evidence for two independent binding interactions within the allosteric specificity site.
Kreis et al. Phenotypic analysis of 1-B-d-arabinofuranosylcytosine deamination in patients treated with high doses and correlation with response

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2225682

Country of ref document: CA

Ref country code: CA

Ref document number: 2225682

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1997 504545

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996923453

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996923453

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1996923453

Country of ref document: EP